Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial

Department of Internal Medicine, Changhua Christian Hospital, Taiwan, R.O.C.
Anticancer research (Impact Factor: 1.83). 08/2012; 32(8):3415-9.
Source: PubMed


Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS).
Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP).
Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients.
Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

Download full-text


Available from: cheng-shyong Chang, Feb 19, 2015
20 Reads
  • Source
    • "Regimen No patients RR% low risk MDS RR% high risk MDS Reference CsA 50 62 40 Shimamoto et al. [74] eATG 25 64 33 Molldrem et al. [75] eATG 96 47 7 Lim et al. [10] eATGþ/CsA 129 37 23 Sloand et al. [7] eATG þ CsA 45 21 19 Passweg et al. [76] anti CD52 29 77 57 Sloand et al. [9] cA2 37 22 ND Raza et al. [77] cA2 10 20 ND Boula et al. [58] Len 148 76 (del 5q) ND List et al. [78] Len 214 43 (non del 5q) ND Raza et al. [79] Len 47 ND 27 Adès et al. [80] Thal 7 50 0 Invernizzi et al. [81] Thal 42 50 0 Chung et al. [82] Anti CD52: Alemtuzumab; eATG: Equine anti thymocyte globulin; cA2: Infliximab; CsA: Cyclosporine; Len: Lenalidomide ND: Not determined; RR: Response rate; Thal: Thalidomide. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) are frequently associated with clinical manifestations of autoimmune disorders (AD) and inflammatory response of the immune system. AD accompanying MDS and CMML include vasculitis, seronegative polyarthritis and neutrophilic dermatosis. Rare AD including relapsing polychondritis is strongly associated with MDS as in a high proportion of those patients MDS is diagnosed during disease course. Antinuclear antibodies (ANA) are frequently found among MDS patients without clinical manifestation of AD. In a subset of patients, MDS and resulting cytopenias appear to be the consequence of auto reactive immunologic activity and may respond to immunosuppressive treatment (IST). Increased release of inflammatory cytokines like tumor necrosis factor-(TNF)-α and interferon (IF)-γ triggers apoptosis of myeloid precursor cells leading to cytopenias. Impaired function of immune cells including cytotoxic, regulatory (Treg), helper (Th17) T cells and NK cells also appears to predict response to IST, outcome and occurrence of AD.
    Best practice & research. Clinical haematology 12/2013; 26(4):327-336. DOI:10.1016/j.beha.2013.09.003 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspired a growing number of studies and clinical trials. As an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeutic candidate, especially for malignant diseases. We review its therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graft-versus-host disease. Most studies have shown satisfactory results, although several have reported the opposite. Aside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examined. The current work includes a discussion of the mechanisms through which the novel biological effects of thalidomide occur, although more studies should be devoted to this aspect. With appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders, particularly refractory and resistant diseases.
    Frontiers of Medicine 07/2013; 7(3). DOI:10.1007/s11684-013-0277-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: The open-label, prospective, observational study aimed to evaluate whether decitabine (DAC) plus thalidomide versus DAC monotherapy improved progression-free (PFS), overall survival (OS) and acute myeloid leukemia-free survival (AML-FS) for risk-tailored elderly patients with myelodysplastic syndromes (MDS). Enrolled 107 patients (age: 65-82 years) received DAC (52/107) or DAC plus thalidomide (55/107) therapy for MDS. 35/52 patients (67.3%) with DAC therapy reached overall response (OR), compared with 36/55 patients (65.5%) in DAC+thalidomide regimen (P>0.05). DAC+thalidomide administered did not gain more profits of PFS and OS than DAC monotherapy. Risk-tailored analysis showed that DAC+thalidomide therapy did not enhance PFS (48.9% versus 42.8%, P>0.05) and OS (78.6% versus 71.2%, P>0.05) when compared with simple DAC regimen. Nevertheless, DAC+thalidomide markedly improved OS over DAC monotherapy (50.6% versus 40.2%, P<0.05) in high risk profile. Meanwhile, low risk group was superior to high risk group in AML-FS (57.2% versus 21.3%, P<0.01), but DAC+thalidomide still did not prolong 2-year AML-FS when compared with DAC (32.4% versus 27.8%, P<0.05). Moreover, thalidomide had a favorable toxicity profile as a single agent. In comparison with DAC monotherapy, the DAC+thalidomide regimen was relatively well tolerated. There was no severe non-hematological toxicity appearing in elderly patients with MDS. The study demonstrated that DAC+thalidomide improved 2-year OS for high risk patients. Thalidomide's proven activity and low toxicity profile made it an alternative treatment option for risk-tailored elderly patients with MDS. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Leukemia Research 02/2015; 39(4). DOI:10.1016/j.leukres.2015.01.014 · 2.35 Impact Factor